Carlsmed Inc (CARL)

$11.34 -0.37 (-3.16%)
Market Cap 308.28M
Revenue (ttm) 50.51M
Net Income (ttm) -29.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -58.66%
Debt to Equity Ratio 0.17
Volume 119,200
Avg Vol 168,438
Day's Range N/A - N/A
Shares Out 27.19M
Stochastic %K 74%
Beta N/A
Analysts Strong Sell
Price Target $18.17

Company Profile

Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorpora...

Industry: Health Information Services
Sector: Healthcare
Phone: 760 766 1923
Address:
1800 Aston Avenue, Suite 100, Carlsbad, United States
ripster47
ripster47 Jul. 1 at 1:11 PM
$CARL | Needham Starts Carlsmed at Buy with $17 PT on Personalized Spine Implant Adoption Needham starts bullish as differentiated aprevo implants, clinical data, and reimbursement tailwinds drive adoption upside. 🔹 Follow @tenet_research for more analyst insights on other tickers.
0 · Reply
SmartAlphaa
SmartAlphaa Jul. 1 at 1:06 PM
$CARL opens higher after Needham initiated coverage with a Buy rating and a $17 price target, highlighting strong adoption potential for its personalized spine implant platform. The call points to differentiated Aprevo technology, improving clinical outcomes data, and supportive reimbursement trends as key drivers for future growth. Early-stage setup, but sentiment is clearly shifting more constructive around commercialization trajectory.
0 · Reply
MarketVisionn1
MarketVisionn1 Jun. 30 at 3:07 PM
I am holding $CARL regardless of the noise. Management is executing, and the industry demand for this tech is massive. We are stronger together. Do not let short sellers steal your discount shares. Close the terminal app and ignore the paper losses. Skin in the game means staying the course.
0 · Reply
Sherwood2020
Sherwood2020 May. 21 at 10:46 PM
$CARL jump on board. Very quiet
0 · Reply
Sherwood2020
Sherwood2020 May. 21 at 2:50 PM
$CARL good start today
0 · Reply
Sherwood2020
Sherwood2020 May. 20 at 5:30 PM
$CARL How high is this going to
0 · Reply
Sherwood2020
Sherwood2020 May. 20 at 11:59 AM
$CARL need a good day!!!!
0 · Reply
fallondpicks
fallondpicks May. 19 at 9:33 PM
18 #stockbreakouts $CARL (base), $CMBT (gap), $DMLP, $IBHF, $PURR (gap). Two sub-$1, four $1-2.
0 · Reply
Sherwood2020
Sherwood2020 May. 19 at 5:22 PM
$CARL close $.65 up
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 5 at 8:10 PM
$CARL Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.32 up 78.23% YoY • Reported revenue of $16.12M up 58.17% YoY • Carlsmed raised its full year 2026 revenue guidance to a range of $72M to $77M, up from prior guidance of $70M to $75M, representing 48% growth at the midpoint over 2025.
0 · Reply
Latest News on CARL
Carlsmed initiated with a Buy at Needham

2026-07-01T10:00:36.000Z - 3 days ago

Carlsmed initiated with a Buy at Needham

Carlsmed Transcript: Truist Securities MedTech Conference 2026

Jun 16, 2026, 10:00 AM EDT - 18 days ago

Carlsmed Transcript: Truist Securities MedTech Conference 2026

Carlsmed Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 7:20 PM EDT - 7 weeks ago

Carlsmed Transcript: Bank of America Global Healthcare Conference 2026

Carlsmed Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

Carlsmed Earnings Call Transcript: Q1 2026

Carlsmed Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

Carlsmed Earnings release: Q1 2026

Carlsmed Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

Carlsmed Quarterly report: Q1 2026

Carlsmed reports Q1 EPS (32c), consensus (40c)

2026-05-05T20:25:49.000Z - 2 months ago

Carlsmed reports Q1 EPS (32c), consensus (40c)

Carlsmed raises FY26 revenue view to $72M-$77M from $70M-$75M

2026-05-05T20:22:13.000Z - 2 months ago

Carlsmed raises FY26 revenue view to $72M-$77M from $70M-$75M

Carlsmed® Reports First Quarter 2026 Financial Results

May 5, 2026, 4:01 PM EDT - 2 months ago

Carlsmed® Reports First Quarter 2026 Financial Results

Carlsmed Slides: Corporate presentation

May 5, 2026, 4:00 PM EDT - 2 months ago

Carlsmed Slides: Corporate presentation

Carlsmed, Inc. To Participate in Upcoming Investor Conferences

Apr 28, 2026, 4:01 PM EDT - 2 months ago

Carlsmed, Inc. To Participate in Upcoming Investor Conferences

Carlsmed Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 2 months ago

Carlsmed Proxy statement: Proxy filing

Carlsmed Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 2 months ago

Carlsmed Proxy statement: Proxy filing

Carlsmed price target lowered to $18 from $20 at Truist

2026-04-15T12:33:56.000Z - 2 months ago

Carlsmed price target lowered to $18 from $20 at Truist

Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026

Apr 14, 2026, 8:00 AM EDT - 2 months ago

Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026

Carlsmed Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 11:45 AM EDT - 2 months ago

Carlsmed Transcript: 25th Annual Needham Virtual Healthcare Conference

Carlsmed price target lowered to $23 from $24 at BTIG

2026-04-13T11:52:20.000Z - 2 months ago

Carlsmed price target lowered to $23 from $24 at BTIG

Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference

Apr 1, 2026, 4:01 PM EDT - 3 months ago

Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference

Carlsmed Transcript: 2026 CG Musculoskeletal Conference

Mar 2, 2026, 12:30 PM EST - 4 months ago

Carlsmed Transcript: 2026 CG Musculoskeletal Conference

Carlsmed Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Carlsmed Earnings Call Transcript: Q4 2025

Carlsmed Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Carlsmed Annual report: Q4 2025

Carlsmed Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Carlsmed Earnings release: Q4 2025

Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 25, 2026, 4:01 PM EST - 4 months ago

Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results

Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference

Feb 23, 2026, 4:01 PM EST - 4 months ago

Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference

Carlsmed announces first procedure with corra Cervical Plating System

2026-02-18T21:36:56.000Z - 4 months ago

Carlsmed announces first procedure with corra Cervical Plating System

Carlsmed Announces first corra™ personalized Cervical Plating Procedure

Feb 18, 2026, 4:05 PM EST - 4 months ago

Carlsmed Announces first corra™ personalized Cervical Plating Procedure

Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Feb 11, 2026, 4:01 PM EST - 5 months ago

Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Carlsmed announces completion of first posterior lumbar spine surgery

2026-02-10T14:12:31.000Z - 5 months ago

Carlsmed announces completion of first posterior lumbar spine surgery

Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Procedure

Feb 10, 2026, 9:00 AM EST - 5 months ago

Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Procedure

Carlsmed sees Q4 revenue $15.2M, up 61% year-over-year

2026-01-12T13:16:05.000Z - 6 months ago

Carlsmed sees Q4 revenue $15.2M, up 61% year-over-year

Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025

Jan 12, 2026, 8:05 AM EST - 6 months ago

Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025

Carlsmed price target raised to $20 from $19 at Goldman Sachs

2026-01-09T10:50:27.000Z - 6 months ago

Carlsmed price target raised to $20 from $19 at Goldman Sachs

Carlsmed publishes new retrospective cohort study in Global Spine

2026-01-06T21:10:25.000Z - 6 months ago

Carlsmed publishes new retrospective cohort study in Global Spine

Carlsmed aprevo® Lumbar 2-year Data Published in Global Spine Journal

Jan 6, 2026, 4:05 PM EST - 6 months ago

Carlsmed aprevo® Lumbar 2-year Data Published in Global Spine Journal

Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare Conference

Dec 16, 2025, 4:01 PM EST - 7 months ago

Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare Conference

Carlsmed Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 9:00 AM EST - 7 months ago

Carlsmed Transcript: Piper Sandler 37th Annual Healthcare Conference

Carlsmed announces U.S. launch of its aprevo Technology Platform

2025-12-03T12:05:32.000Z - 7 months ago

Carlsmed announces U.S. launch of its aprevo Technology Platform

Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting

Dec 3, 2025, 7:00 AM EST - 7 months ago

Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting

Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 4:01 PM EST - 8 months ago

Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference

Carlsmed price target raised to $24 from $21 at BTIG

2025-11-07T12:20:26.000Z - 8 months ago

Carlsmed price target raised to $24 from $21 at BTIG

Carlsmed Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Carlsmed Earnings Call Transcript: Q3 2025

Carlsmed Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Carlsmed Quarterly report: Q3 2025

Carlsmed Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Carlsmed Earnings release: Q3 2025

Carlsmed raises FY25 revenue view to $49M-$50M from $45.5M-$47.5M

2025-11-06T21:12:54.000Z - 8 months ago

Carlsmed raises FY25 revenue view to $49M-$50M from $45.5M-$47.5M

Carlsmed reports Q3 EPS (40c), consensus (49c)

2025-11-06T21:05:17.000Z - 8 months ago

Carlsmed reports Q3 EPS (40c), consensus (49c)

Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance

Nov 6, 2025, 4:01 PM EST - 8 months ago

Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance

Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 23, 2025, 4:01 PM EDT - 9 months ago

Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025

Carlsmed appoints Jennifer Kamocsay as CLO, secretary

2025-09-29T13:20:37.000Z - 9 months ago

Carlsmed appoints Jennifer Kamocsay as CLO, secretary

Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary

Sep 29, 2025, 9:00 AM EDT - 9 months ago

Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary

Carlsmed announces inclusion in Russell 2000 Index

2025-09-22T13:20:21.000Z - 10 months ago

Carlsmed announces inclusion in Russell 2000 Index

Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index

Sep 22, 2025, 9:00 AM EDT - 10 months ago

Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index

UPDATE - Carlsmed® Reports Second Quarter 2025 Financial Results

Aug 28, 2025, 6:09 PM EDT - 11 months ago

UPDATE - Carlsmed® Reports Second Quarter 2025 Financial Results

Carlsmed Earnings Call Transcript: Q2 2025

Aug 28, 2025, 4:30 PM EDT - 11 months ago

Carlsmed Earnings Call Transcript: Q2 2025

Carlsmed Quarterly report: Q2 2025

Aug 28, 2025, 4:30 PM EDT - 11 months ago

Carlsmed Quarterly report: Q2 2025

Carlsmed Earnings release: Q2 2025

Aug 28, 2025, 4:30 PM EDT - 11 months ago

Carlsmed Earnings release: Q2 2025

Carlsmed reports Q2 revenue $12.1M, consensus $11.99M

2025-08-28T20:05:24.000Z - 11 months ago

Carlsmed reports Q2 revenue $12.1M, consensus $11.99M

Carlsmed sees FY25 revenue $45.5M-$47.5M, consensus $45.67M

2025-08-28T20:05:11.000Z - 11 months ago

Carlsmed sees FY25 revenue $45.5M-$47.5M, consensus $45.67M

Carlsmed® Reports Second Quarter 2025 Financial Results

Aug 28, 2025, 4:01 PM EDT - 11 months ago

Carlsmed® Reports Second Quarter 2025 Financial Results

Carlsmed Inc. to Report Second Quarter 2025 Financial Results on August 28, 2025

Aug 14, 2025, 9:05 AM EDT - 11 months ago

Carlsmed Inc. to Report Second Quarter 2025 Financial Results on August 28, 2025

Carlsmed's aprevo® Personalized Interbody Implants Receive CMS New Technology Add-On Payment (NTAP) for Cervical Fusion Procedures

Aug 1, 2025, 9:05 AM EDT - 1 year ago

Carlsmed's aprevo® Personalized Interbody Implants Receive CMS New Technology Add-On Payment (NTAP) for Cervical Fusion Procedures

Carlsmed's aprevo® Powers First Personalized Cervical Spine Surgery

Jul 28, 2025, 9:05 AM EDT - 1 year ago

Carlsmed's aprevo® Powers First Personalized Cervical Spine Surgery

Carlsmed Announces Pricing of Initial Public Offering

Jul 22, 2025, 8:03 PM EDT - 1 year ago

Carlsmed Announces Pricing of Initial Public Offering

Carlsmed Announces Launch of Initial Public Offering

Jul 22, 2025, 7:20 PM EDT - 1 year ago

Carlsmed Announces Launch of Initial Public Offering

ripster47
ripster47 Jul. 1 at 1:11 PM
$CARL | Needham Starts Carlsmed at Buy with $17 PT on Personalized Spine Implant Adoption Needham starts bullish as differentiated aprevo implants, clinical data, and reimbursement tailwinds drive adoption upside. 🔹 Follow @tenet_research for more analyst insights on other tickers.
0 · Reply
SmartAlphaa
SmartAlphaa Jul. 1 at 1:06 PM
$CARL opens higher after Needham initiated coverage with a Buy rating and a $17 price target, highlighting strong adoption potential for its personalized spine implant platform. The call points to differentiated Aprevo technology, improving clinical outcomes data, and supportive reimbursement trends as key drivers for future growth. Early-stage setup, but sentiment is clearly shifting more constructive around commercialization trajectory.
0 · Reply
MarketVisionn1
MarketVisionn1 Jun. 30 at 3:07 PM
I am holding $CARL regardless of the noise. Management is executing, and the industry demand for this tech is massive. We are stronger together. Do not let short sellers steal your discount shares. Close the terminal app and ignore the paper losses. Skin in the game means staying the course.
0 · Reply
Sherwood2020
Sherwood2020 May. 21 at 10:46 PM
$CARL jump on board. Very quiet
0 · Reply
Sherwood2020
Sherwood2020 May. 21 at 2:50 PM
$CARL good start today
0 · Reply
Sherwood2020
Sherwood2020 May. 20 at 5:30 PM
$CARL How high is this going to
0 · Reply
Sherwood2020
Sherwood2020 May. 20 at 11:59 AM
$CARL need a good day!!!!
0 · Reply
fallondpicks
fallondpicks May. 19 at 9:33 PM
18 #stockbreakouts $CARL (base), $CMBT (gap), $DMLP, $IBHF, $PURR (gap). Two sub-$1, four $1-2.
0 · Reply
Sherwood2020
Sherwood2020 May. 19 at 5:22 PM
$CARL close $.65 up
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 5 at 8:10 PM
$CARL Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.32 up 78.23% YoY • Reported revenue of $16.12M up 58.17% YoY • Carlsmed raised its full year 2026 revenue guidance to a range of $72M to $77M, up from prior guidance of $70M to $75M, representing 48% growth at the midpoint over 2025.
0 · Reply
gaineous
gaineous Apr. 24 at 2:05 PM
Who’s $CARL and how does he know $ATEC
0 · Reply
Greyhound9
Greyhound9 Apr. 22 at 5:31 PM
$CADL Sorry, it really has to be in English 😳🙈😃 $CARL The 7.50 is a bit of an obstacle right now. Come on, let's raise it higher. 💪🏻😉
1 · Reply
focafoca99
focafoca99 Apr. 1 at 9:47 PM
$CARL is flagging participation in the Needham virtual conference.
0 · Reply
PurpleSquirrel2020
PurpleSquirrel2020 Mar. 20 at 8:57 PM
$CARL this is a $20+ stock all day someday…. Just not today…
0 · Reply
ap20
ap20 Mar. 11 at 10:38 PM
$CARL Really great setup for early investors. 55 watchers! Personalized spine surgery using AI to create customized spine devices. Already growing rapidly. I saw their last earnings report and totally fell for it. Good luck all.
0 · Reply
PurpleSquirrel2020
PurpleSquirrel2020 Mar. 5 at 11:46 PM
$CARL decent volume in last 10 minutes of the day.ending at 147k . Director of company Michael Condonnier filed to sell nearly 200k shares of his 1.55 mil he owned. That may be weighing on the shares price. Should be short lived imo.
0 · Reply
StockScanners
StockScanners Feb. 28 at 7:27 PM
$CARL reached 15.19
0 · Reply
StockScanners
StockScanners Feb. 27 at 4:34 AM
$CARL keep watch if this holds above 14
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 25 at 10:23 PM
$CARL Q4 '25 Earnings Results & Recap Carlsmed anticipates gross margin to remain constant short-term and modestly increase medium-to-long-term due to efficiencies. The company also expects broader commercialization of its aprevo cervical platform in 2026.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 22 at 9:28 PM
$CARL Current Stock Price: $12.79
0 · Reply
SentimentSwings
SentimentSwings Feb. 18 at 3:36 PM
$CARL Carlyle Secured Lending is a BDC focused on first-lien loans. Yield is attractive but tied to credit health. NAV stability is the key performance metric.
1 · Reply